What Enveric Biosciences’ EB-003 data reveal about separating benefit from hallucinations
Enveric Biosciences reports new EB-003 signaling data. Find out what this means for non-hallucinogenic antidepressant development and regulatory risk.
What Evecxia’s EVX-301 trial reveals about the future of serotonin-based psychiatry
Evecxia’s Phase 1b study uses direct brain biomarkers to validate serotonin synthesis amplification. Find out why this matters for antidepressant development.